Fosun Pharma (600196, 02196) Announces Acceptance of Subsidiary’s Cyclophosphamide Injection Registration

Bulletin Express02-05

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) reported that its subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the registration application of Cyclophosphamide Injection. The product is a chemical drug intended for the treatment of various cancers, including malignant lymphomas, Hodgkin’s disease, lymphocytic lymphoma, and multiple myeloma.

According to the announcement, Fosun Pharma has invested approximately RMB7.40 million in the development of Cyclophosphamide Injection as of December 2025. Referencing IQVIA CHPA data, sales of this injection in China reached around RMB291 million in 2024. The latest acceptance marks a step forward in the approval process but is not expected to materially affect the group’s results at this stage. The overall sales performance following any eventual market launch remains subject to market factors and competition.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122558021?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122558021","market":"hk","top_or_hot":-1,"title":"Fosun Pharma (600196, 02196) Announces Acceptance of Subsidiary’s Cyclophosphamide Injection Registration","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) reported that its subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the registration application of Cyclophosphamide Injection. The product is a chemical drug intended for the treatment of various cancers, including malignant lymphomas, Hodgkin’s disease, lymphocytic lymphoma, and multiple myeloma.</p>\n<p>According to the announcement, Fosun Pharma has invested approximately RMB7.40 million in the development of Cyclophosphamide Injection as of December 2025. Referencing IQVIA CHPA data, sales of this injection in China reached around RMB291 million in 2024. The latest acceptance marks a step forward in the approval process but is not expected to materially affect the group’s results at this stage. The overall sales performance following any eventual market launch remains subject to market factors and competition.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma (600196, 02196) Announces Acceptance of Subsidiary’s Cyclophosphamide Injection Registration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma (600196, 02196) Announces Acceptance of Subsidiary’s Cyclophosphamide Injection Registration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-05 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) reported that its subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the registration application of Cyclophosphamide Injection. The product is a chemical drug intended for the treatment of various cancers, including malignant lymphomas, Hodgkin’s disease, lymphocytic lymphoma, and multiple myeloma.</p>\n<p>According to the announcement, Fosun Pharma has invested approximately RMB7.40 million in the development of Cyclophosphamide Injection as of December 2025. Referencing IQVIA CHPA data, sales of this injection in China reached around RMB291 million in 2024. The latest acceptance marks a step forward in the approval process but is not expected to materially affect the group’s results at this stage. The overall sales performance following any eventual market launch remains subject to market factors and competition.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1122558021","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122558021","pubTimestamp":1770284808,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) reported that its subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(600196, 02196)公告子公司环磷酰胺注射液注册受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) reported that its subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the registration application of Cyclophosphamide Injection. The product is a chemical drug intended for the treatment of various cancers, including malignant lymphomas, Hodgkin’s disease, lymphocytic lymphoma, and multiple myeloma.\nAccording to the announcement, Fosun Pharma has invested approximately RMB7.40 million in the development of Cyclophosphamide Injection as of December 2025. Referencing IQVIA CHPA data, sales of this injection in China reached around RMB291 million in 2024. The latest acceptance marks a step forward in the approval process but is not expected to materially affect the group’s results at this stage. The overall sales performance following any eventual market launch remains subject to market factors and competition.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122558021","isCrawlerRequest":true}